Pharma BD Deal Intelligence
BMS licensed BioArctic's Alzheimer's antibodies BAN1503 and BAN2803 in a deal valued at $1.35B, betting on a next-generation anti-amyloid approach as the field's economics remain unproven. The bet's payoff hinges entirely on clinical data that hasn't yet materialized.
BMS taps Eisai's Alzheimer's partner BioArctic in $1.35B deal; anti-pyroglutamate amyloid approach is differentiated but field has mixed track record
Bristol Myers Squibb invests $100M in BioArctic for next-generation Alzheimer's therapies using BrainTransporter technology.
BioArctic Q1 2026 interim report: BMS solely responsible for development and commercialization of BAN1503 and BAN2803; program remains preclinical, no…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
BMS licensed BioArctic's anti-amyloid antibodies BAN1503 and BAN2803 for Alzheimer's disease development and commercialization.
6.7M US cases/yr · $10.0B US Alzheimer's Rx Market
Alzheimer's disease is the most common cause of dementia, characterized by progressive cognitive decline. Anti-amyloid antibodies (Leqembi, Kisunla) showed modest clinical benefit but carry ARIA risk. BioArctic's pyroglutamate-targeting approach may offer differentiated efficacy.
BAN1503 and BAN2803 target pyroglutamate-modified amyloid-beta, a more toxic aggregate form. BAN2803 uses BrainTransporter BBB-crossing technology. Competes with Leqembi (Eisai/Biogen), Kisunla (Lilly), and emerging tau-targeting approaches.
Bristol Myers Squibb's global license of BioArctic's PyroGlutamate-amyloid-beta antibody program (BAN1503 and BAN2803) became effective on 2025-02-20 following U.S. FTC antitrust clearance. BioArctic received a USD 100M upfront payment and is eligible for up to USD 1.25B in development, regulatory and commercial milestones plus tiered low double-digit royalties (total up to USD 1.35B). BMS is solely responsible for worldwide development and commercialization; BioArctic retains a Nordic co-commercialization option. This is a license, not an acquisition.
Deal effective Feb 2025 (FTC-cleared). Preclinical anti-amyloid / pyroglutamate antibody programs (BAN1503, BAN2803) under BMS sole control; as of Q1 2026 not yet in the clinic. Assessment of BMS's $1.35B biobucks license of BioArctic's PyroGlu-Abeta program: early-stage, differentiated approach, milestone-weighted.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / BioArctic AB (this deal) | 2024 | $1.4B | 65 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2024 deals · Bristol-Myers Squibb Company deals · Neurology deals